Features Partner Sites Information LinkXpress hp
Sign In
Advertise with Us

Download Mobile App




Biosensor Technology Will Offer Immunoassay at POC

By LabMedica International staff writers
Posted on 29 Dec 2008
A unique biosensor technology has the potential to offer lab-quality immunoassay results at point of care (POC).

The new technology, Magnotech, offers the possibility of taking certain complex in vitro diagnostic tests out of the laboratory and into a decentralized setting--including critical care treatment centers, ambulances, general practitioner clinics, and the home. More...
Its biggest impact is likely to be on improved patient outcomes and reduced healthcare costs.

Integrated into a disposable biosensor cartridge that inserts into a hand-held analyzer, Magnotech uses magnetic nanoparticles to measure target molecules in very low, picomolar concentrations in blood or saliva--in a few minutes. The main features of the Magnotech technology are: small sample volumes, ease of use, multianalyte systems, sensitive lab results, and speed.

Philips has demonstrated proof-of-concept for its new biosensor technology in a variety of biologic assays, including sandwich assays for the detection of cardiac Troponin I (cTnI), parathyroid hormone (PTH), and inhibition assays to detect several drugs-of-abuse molecules.

Currently, measuring very low concentrations of biomarkers for the diagnosis of, for example, cardiovascular disease, requires laboratory analysis, large sample volumes, and a time-to-result delay of between 30-60 min.

Royal Philips Electronics (Eindhoven, the Netherlands) unveiled the unique biosensor technology, Magnotech, on November 19-22 at Medica 2008, in Dusseldorf, Germany. Marcel van Kasteel, vice president and CEO of Philips Handheld Immunoassays, explained, "Longterm, we envisage that different testing stations--both conventional, automated labs, and these new, mobile handheld systems--will be part of a diagnostic network, using wired or wireless connectivity and sophisticated healthcare informatics solutions to store and assist in interpreting the data. Clinical decision support systems and data mining would be used to enable fast and accurate decision making."

Magnotech is the brainchild of Prof. Dr. Menno Prins, a research fellow at Philips Research, and professor at the Eindhoven University of Technology (TUE; Eindhoven, the Netherlands) where he is head of the "Molecular Biosensors for Medical Diagnostics” group.

Please see related links below for a video demonstrating the Magnotech technology.

Royal Philips Electronics is a leader in healthcare, lifestyle, and lighting. The company integrates technologies and design into people-centric solutions, based on fundamental customer needs and insights.

Related Links:
Royal Philips Electronics
Eindhoven University of Technology
Video: Magnotech technology


Gold Member
Fibrinolysis Assay
HemosIL Fibrinolysis Assay Panel
POC Helicobacter Pylori Test Kit
Hepy Urease Test
HBV DNA Test
GENERIC HBV VIRAL LOAD VER 2.0
Pipette
Accumax Smart Series
Read the full article by registering today, it's FREE! It's Free!
Register now for FREE to LabMedica.com and get access to news and events that shape the world of Clinical Laboratory Medicine.
  • Free digital version edition of LabMedica International sent by email on regular basis
  • Free print version of LabMedica International magazine (available only outside USA and Canada).
  • Free and unlimited access to back issues of LabMedica International in digital format
  • Free LabMedica International Newsletter sent every week containing the latest news
  • Free breaking news sent via email
  • Free access to Events Calendar
  • Free access to LinkXpress new product services
  • REGISTRATION IS FREE AND EASY!
Click here to Register








Channels

Molecular Diagnostics

view channel
Image: The diagnostic device can tell how deadly brain tumors respond to treatment from a simple blood test (Photo courtesy of UQ)

Diagnostic Device Predicts Treatment Response for Brain Tumors Via Blood Test

Glioblastoma is one of the deadliest forms of brain cancer, largely because doctors have no reliable way to determine whether treatments are working in real time. Assessing therapeutic response currently... Read more

Microbiology

view channel
Image: New evidence suggests that imbalances in the gut microbiome may contribute to the onset and progression of MCI and Alzheimer’s disease (Photo courtesy of Adobe Stock)

Comprehensive Review Identifies Gut Microbiome Signatures Associated With Alzheimer’s Disease

Alzheimer’s disease affects approximately 6.7 million people in the United States and nearly 50 million worldwide, yet early cognitive decline remains difficult to characterize. Increasing evidence suggests... Read more

Technology

view channel
Image: Vitestro has shared a detailed visual explanation of its Autonomous Robotic Phlebotomy Device (photo courtesy of Vitestro)

Robotic Technology Unveiled for Automated Diagnostic Blood Draws

Routine diagnostic blood collection is a high‑volume task that can strain staffing and introduce human‑dependent variability, with downstream implications for sample quality and patient experience.... Read more

Industry

view channel
Image: Roche’s cobas® Mass Spec solution enables fully automated mass spectrometry in routine clinical laboratories (Photo courtesy of Roche)

New Collaboration Brings Automated Mass Spectrometry to Routine Laboratory Testing

Mass spectrometry is a powerful analytical technique that identifies and quantifies molecules based on their mass and electrical charge. Its high selectivity, sensitivity, and accuracy make it indispensable... Read more
Copyright © 2000-2026 Globetech Media. All rights reserved.